全球特發性肺纖維化（IPF）治療藥物市場（2023-2030）：類型（吡非尼酮、尼達尼布）、配銷通路（醫院藥房、零售藥房、線上提供者）、規模、佔有率、成長分析、預測

全球特發性肺纖維化（IPF）治療市場規模預計將從2021年的33.1億美元成長到2022年的35.4億美元，預測期內年複合成長率為6.8%，到2030年預計將成長到美國2019 年為59.9 億美元。

近年來，全球IPF藥物市場經歷了顯著的成長和進步。特發性肺纖維化是一種慢性進行性肺部疾病，其特徵是肺組織疤痕和增厚，導致呼吸困難和肺功能下降。該市場受到 IPF 盛行率增加、老年人口增加以及對該疾病認知不斷提高等因素的推動。此外，高解析度電腦斷層掃描 (HRCT) 等診斷技術的進步和新型治療方法的開發也有助於市場成長。 IPF 的治療方案包括吡非尼酮和尼達尼布等藥物干涉措施，這些干涉措施已獲得法規機構核准，可減緩疾病進展。此外，對於合格的末期 IPF 患者，肺移植被認為是可行的治療選擇。近年來，研發活動增加，導致潛在治療標靶和有前途的候選藥物的出現。此外，市場開始看到製藥公司和研究機構之間的合作和夥伴關係，以加速有效治療方案的發展。

然而，挑戰仍然存在，例如治療費用高、新興地區患者意識低、缺乏明確的治療方法等。

本報告調查了全球特發性肺纖維化（IPF）治療藥物市場，並提供了市場概況、市場各種影響因素分析、技術和創新趨勢、法律制度以及市場規模趨勢和預測。按不同分類和地區分類，競爭形勢、主要企業概況等

目錄

• 執行摘要
• 調查方法
• 母市場分析
  • 市場概況
  • 市場規模
  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
• 關鍵市場洞察
  • 技術分析
  • 價格分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • 啟動分析
  • 原料分析
  • 創新矩陣
  • 研發線產品分析
  • 總體經濟指標
  • 重點投資分析
  • 關鍵成功因素
  • 競爭程度
  • 市場動態及展望
    • 市場動態
      • 促進因素
      • 機會
      • 抑制因素
      • 任務
  • 法規狀況
  • 波特的分析
  • Skyquest 對未來顛覆的獨家見解
• 按類型分類的全球特發性肺纖維化 (IPF) 治療市場
  • 市場概況
  • 吡非尼酮
  • 尼達尼布
• 按配銷通路的全球特發性肺纖維化（IPF）治療市場
  • 市場概況
  • 醫院藥房
  • 零售藥房/線上提供者
• 按地區分類的全球特發性肺纖維化（IPF）治療市場
  • 市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲
• 競爭形勢
  • 前5名企業對比
  • 主要企業市場地位
  • 主要企業的招募策略
  • 關鍵成功策略
  • 近期市集活動
  • 主要企業市場佔有率
• 主要企業簡介
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim
  • GNI Group Ltd
  • F. Hoffmann-La Roche Ltd.
  • Shiongi co Ltd
  • Mission Therapeutics
  • Biogen, Inc.
  • Galapagos NV
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Genzyme Corporation
  • Actelion Pharmaceuticals Ltd
  • Promedior, Inc.
  • MediciNova, Inc.
  • Cipla Limited
  • InterMune, Inc.
  • Phytopharm plc
  • Galecto Biotech AB
  • Celtaxsys, Inc.

Global Idiopathic Pulmonary Fibrosis Treatment Market size was valued at USD 3.31 Billion in 2021 and is poised to grow from USD 3.54 Billion in 2022 to USD 5.99 Billion by 2030, at a CAGR of 6.8% during the forecast period (2023-2030).

The Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market has witnessed significant growth and advancements in recent years. Idiopathic pulmonary fibrosis is a chronic and progressive lung disorder characterized by the scarring and thickening of lung tissues, leading to breathing difficulties and reduced lung function. The market for IPF treatment has been driven by factors such as increasing prevalence of IPF, growing geriatric population, and rising awareness about the disease. Furthermore, advancements in diagnostic techniques, such as high-resolution computed tomography (HRCT), and the development of novel therapies have also contributed to the market growth. The treatment landscape for IPF includes pharmacological interventions, such as pirfenidone and nintedanib, which are approved by regulatory authorities for slowing down disease progression. Additionally, lung transplantation is considered as a viable treatment option for eligible patients with end-stage IPF. In recent years, there has been a surge in research and development activities, leading to the emergence of potential therapeutic targets and promising drug candidates. Moreover, the market is witnessing collaborations and partnerships between pharmaceutical companies and research institutions to accelerate the development of effective treatment options. However, challenges such as high treatment costs, limited patient awareness in developing regions, and the lack of definitive curative therapies still persist. Nevertheless, the global IPF treatment market is expected to continue its growth trajectory, driven by ongoing research, technological advancements, and a growing focus on improving the quality of life for IPF patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Emergency Lighting Systems Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Idiopathic Pulmonary Fibrosis Treatment Market Segmental Analysis

The Global Idiopathic Pulmonary Fibrosis Treatment Market is segmented on the basis of type, distribution channel, and region. Based on type, the market can be segmented into Pirfenidone and nintedanib. Based on distribution channel, the market is segmented into Hospital pharmacies, retail pharmacies and online providers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Idiopathic Pulmonary Fibrosis Treatment Market Dynamics

Drivers of the Global Idiopathic Pulmonary Fibrosis Treatment Market

Increasing prevalence of IPF

One key driver of the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing prevalence of IPF. The rising incidence of IPF globally, particularly among the aging population, is driving the demand for effective treatment options. As the number of diagnosed IPF cases continues to grow, there is a greater need for pharmaceutical interventions and therapies that can slow down disease progression and improve patients' quality of life.

Restraints in the Global Idiopathic Pulmonary Fibrosis Treatment Market

High treatment costs

One key restraint of the IPF treatment market is the high treatment costs. The cost of IPF treatment, including medications, diagnostic tests, and supportive care, can be significant and pose a financial burden on patients and healthcare systems. The high cost of treatment may limit access to effective therapies, especially in regions with limited healthcare resources or inadequate insurance coverage. This can result in disparities in treatment availability and affordability, impacting patients' ability to access appropriate care and potentially leading to suboptimal outcomes.

Market Trends of Global Idiopathic Pulmonary Fibrosis Treatment Key

Increasing focus on personalized medicine and precision therapeutics

One key market trend in the Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market is the increasing focus on personalized medicine and precision therapeutics. With advancements in understanding the underlying mechanisms and heterogeneity of IPF, there is a growing emphasis on tailoring treatment approaches based on individual patient characteristics and disease subtypes. This trend involves the identification of biomarkers, genetic profiling, and the development of targeted therapies that can address specific molecular pathways associated with IPF progression. The aim is to improve treatment outcomes by providing more precise and effective therapies that have the potential to slow down disease progression and improve patients' quality of life.

Table of Contents

• Executive Summary
  • Market Overview
  • Wheel of Fortune
• Research Methodology
  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations
• Parent Market Analysis
  • Market Overview
  • Market Size
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition
• Market Dynamics & Outlook
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
  • Regulatory Landscape
  • Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Idiopathic Pulmonary Fibrosis Treatment Market by Type
  • Market Overview
  • Pirfenidone and nintedanib
• Global Idiopathic Pulmonary Fibrosis Treatment Market by Distribution channel
  • Market Overview
  • Hospital pharmacies
  • retail pharmacies and online providers
• Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Region
  • Market Overview
  • North America
• USA
• Canada
  • Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
  • Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
  • Latin America
• Brazil
• Rest of Latin America
  • Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
• By Development
• By Company
• By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
• Key Company Profiles
  • AstraZeneca PLC (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Bristol-Myers Squibb Company (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Boehringer Ingelheim (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GNI Group Ltd (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • F. Hoffmann-La Roche Ltd. (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Shiongi co Ltd (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Mission Therapeutics (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Biogen, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Galapagos NV (Belgium)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • FibroGen, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • GlaxoSmithKline plc (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Genzyme Corporation (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Actelion Pharmaceuticals Ltd (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Promedior, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • MediciNova, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Cipla Limited (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • InterMune, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Phytopharm plc (UK)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Galecto Biotech AB (Sweden)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Celtaxsys, Inc. (US)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments